---
schema_version: "secwatch.filing_event.v1"
accession: "0001104659-26-010036"
form_type: "8-K"
ticker: "VSTM"
cik: "0001526119"
company_name: "Verastem, Inc."
filed_at: "2026-02-04T23:59:59+00:00"
generated_at: "2026-05-16T04:54:37.675136+00:00"
event_type: "earnings"
sentiment: "positive"
materiality_score: 0.65
calibrated_materiality_score: 0.65
confidence: "high"
source: SEC EDGAR
---

# Verastem reports preliminary 2025 product revenue $30.9M; cash runway to H1 2027

## Summary
- Preliminary AVMAPKI FAKZYNJA CO-PACK net revenue: Q4 2025 ~$17.5M, full year 2025 ~$30.9M (launch from May 2025).
- Cash, equivalents, investments $205M at Dec 31, 2025; pro-forma $234M netting $29.4M from warrant exercises.
- Anticipates LGSOC commercial launch and development to be self-sustaining by 2H 2026.
- VS-7375 KRAS G12D inhibitor: interim Phase 1/2 update in 1H 2026; FDA discussions on registration-directed trials planned.
- RAMP 205 PDAC expansion cohort update with ≥6 months follow-up expected in Q2 2026.

## SEC filing metadata
- accession: 0001104659-26-010036
- form_type: 8-K
- ticker: VSTM
- cik: 0001526119
- company_name: Verastem, Inc.
- filed_at: 2026-02-04T23:59:59+00:00
- event_type: earnings
- sentiment: positive
- materiality_score: 0.65
- calibrated_materiality_score: 0.65
- confidence: high
- sec_items: 2.02, 7.01, 9.01
- EDGAR index: https://www.sec.gov/Archives/edgar/data/1526119/000110465926010036/0001104659-26-010036-index.htm
- EDGAR primary document: https://www.sec.gov/Archives/edgar/data/1526119/000110465926010036/tm265057d1_8k.htm

## Machine-readable alternates
- HTML: https://secwatch.observer/filing/0001104659-26-010036
- JSON: https://secwatch.observer/filing/0001104659-26-010036.json
- Plain text: https://secwatch.observer/filing/0001104659-26-010036.txt

This AI-assisted summary is a reading aid. Review the linked SEC EDGAR filing before relying on any specific claim.